6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2019

Commission File Number: 001-32371

SINOVAC BIOTECH LTD.

No. 15 Zhi Tong Road

Zhongguancun Science and Technology Park

Changping District

Beijing 102200, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F          x         Form 40-F         ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):________________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):________________

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SINOVAC BIOTECH LTD.
By:	/s/ Nan Wang
Name:	Nan Wang
Title:	Chief Financial Officer

Date: November 18, 2019

Exhibit Index

Exhibit 99.1 Press Release

EX-99.1

Exhibit 99.1

Sinovac Reports Unaudited Third Quarter 2019 Financial Results

BEIJING, China, Novermber 15, 2019 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2019.

Third Quarter and First Nine Months of 2019 Financial Summary

·  Sales for the third quarter of 2019 were $64.3 million, an increase of 19.3% from $53.9 million in the prior year period.

·  Sales for the nine months ended September 30, 2019, were $164.9 million, a decrease of 6.5% from $176.4 million in the prior year period. $8.9 million of this decrease is attributable to changes in the exchange rate between the U.S. dollar and Chinese renminbi.

·  Operating income for the third quarter decreased 15.7% from the prior year period due to a change in sales mix, with a greater proportion of revenue generated from the lower-margin influenza vaccine.

·  Operating income for the nine months ended September 30, 2019, decreased 11.7% from the prior year period due to lower sales.

·  The Company posted $6.3 million of net income attributable to common shareholders, or $0.06 per basic and diluted share in the third quarter, compared to net income attributable to common shareholders of $8.9 million, or $0.12 per basic and diluted share, in the prior year period.

·  The Company posted $18.1 million of net income attributable to common shareholders, or $0.19 per basic and diluted share in the nine months ended September 30, 2019, compared to net income attributable to common shareholders of $22.9 million, or $0.37 per basic and $0.36 per diluted share, in the prior year period.

Mr. Weidong Yin, Chairman, President, and CEO of Sinovac, commented, “We delivered sales growth this quarter despite facing challenges from market demand for some of our vaccines and a lack of supply of certain products. We are pleased to report that during the quarter, Anflu, the seasonal influenza vaccine, was relaunched to the market after a one-year absence due to the manufacturing disruption orchestrated by the minority shareholder of our Beijing operation last year.”

“We have made strong progress in our pipeline development in 2019, and we expect the commercial launches of varicella, sIPV, and QIV in 2020. We also welcome the implementation of the new vaccine legislation, which will ultimately benefit high-quality vaccine manufacturers such as Sinovac as well as public health in China,” Mr. Yin concluded.

Pipeline Development

Varicella –The Company filed an application for a production license for its varicella vaccine with the National Medical Products Administration (“NMPA”), previously known as the China State Food and Drug Administration, in November 2017. The site inspection by the NMPA in July 2019 was successfully passed. The Company expects the license to be issued in early 2020.

23-valent Pneumococcal polysaccharide vaccine (or PPV-23) – The Company submitted its application for a production license in 2017. In 2018, the NMPA requested a supplementary submission. The technical review by NMPA was completed at the end of September and a notice of site inspection was issued to the Company. The on-site inspection is currently being prepared. The Company expects the license to be issued in 2021.

Quadrivalent influenza vaccine (or QIV) – The Company filed an application with the NMPA for a production license for the QIV vaccine in March 2019. Preliminary questions and answers have been submitted. Sinovac’s application is currently under review, and the Company expects the production license to be issued in 2020.

Sabin Inactivated Polio vaccine (or sIPV) – The production license application for the sIPV vaccine was accepted by the NMPA in January 2019. In March 2019, given the high demand for effective polio vaccines, the application was granted fast track review. Currently, the application is under review. The Company expects the license to be issued in 2020.

Unaudited Financial Results for the Third Quarter of 2019

Summary of sales and gross profit

	2019					2018
(In $000 except percentage data)	Q3		% of Sales			Q3		% of Sales
Hepatitis A vaccine – Healive®		14,689		22.8	%		10,040		18.6	%
Hepatitis A&B vaccine – Bilive®		-		-			946		1.8	%
Hepatitis vaccines subtotal		14,689		22.8	%		10,986		20.4	%
Influenza vaccine		12,966		20.2	%		14		0.0	%
EV71 vaccine - Inlive®		32,471		50.4	%		42,542		78.8	%
Mumps vaccine		4,217		6.6	%		407		0.8	%
Total sales		64,343		100.0	%		53,949		100.0	%
Cost of sales		10,347		16.1	%		4,654		8.6	%
Gross profit		53,996		83.9	%		49,295		91.4	%

Sales for the third quarter of 2019 were $64.3 million, an increase of 19.3% from $53.9 million in the prior year period. The increase was due to higher sales of influenza vaccines.

The lack of Bilive^® sales is still attributed to the suspended production of the product, which was due to a lack of supply of the hepatitis B vaccine from the Company’s sole supplier.

2

Gross profit in the third quarter of 2019 was $54.0 million compared to gross profit of $49.3 million in the prior year period. Gross margin was 83.9% compared to 91.4% in the prior year period. The decrease of gross margin was due to a change of sales mix, primarily caused by increased sales of the lower-margin influenza vaccine.

Selling, general and administrative expenses in the third quarter of 2019 were $34.4 million compared to $28.5 million in the prior year period. The Company incurred higher selling expenses in the third quarter of 2019 due to higher sales and marketing activities.

R&D expenses in the third quarter of 2019 were $5.7 million, compared to $4.7 million in the prior year period, as the Company continued to invest in the development of its pipeline of product candidates, including sIPV, PPV, and the varicella vaccine.

Net income in the third quarter of 2019 was $11.7 million compared to $13.2 million in the prior year period. Net income decreased as a higher proportion of revenue was generated from the lower-margin influenza vaccines.

Net income attributable to common shareholders was $6.3 million, or $0.06 per basic and diluted share, compared to net income attributable to common shareholders of $8.9 million, or $0.12 per basic and diluted share, in the prior year period.

As the Company announced on February 22, 2019, the Company’s Board of Directors determined that certain shareholders became “Acquiring Persons,” as defined in the Company’s Rights Agreement (“Rights Agreement”), and a “Trigger Event” occurred under the Rights Agreement. As a result, new common and preferred shares of the Company were issued. Without the effect of the implementation of the Rights Agreement and the newly issued common and preferred shares, basic and diluted earnings per share for the third quarter of 2019 would be $0.11.

Non-GAAP adjusted EBITDA was $15.8 million in the third quarter of 2019 compared to $18.4 million in the prior year period. Non-GAAP net income in the third quarter of 2019 was $12.5 million compared to $14.9 million in the prior year period. Non-GAAP diluted earnings per share in the third quarter of 2019 were $0.07 per share compared to $0.14 per share in the prior year period. Non-GAAP diluted earnings per share in the third quarter of 2019 excluding the implementation of the Rights Agreement and the newly issued common and preferred shares would be $0.12 per share. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement.

3

Unaudited Financial Results for the Nine Months Ended September 30, 2019

Summary of sales and gross profit

	2019					2018
(In $000 except percentage data)	YTD		% of Sales			YTD		% of Sales
Hepatitis A vaccine – Healive®		39,090		23.7	%		35,892		20.3	%
Hepatitis A&B vaccine – Bilive®		-		-			11,290		6.4	%
Hepatitis vaccines subtotal		39,090		23.7	%		47,182		26.7	%
Influenza vaccine		12,966		7.9	%		2,078		1.2	%
EV 71 vaccine - Inlive®		105,697		64.0	%		126,655		71.8	%
Mumps vaccine		7,189		4.4	%		524		0.3	%
Total sales		164,942		100.0	%		176,439		100.0	%
Cost of sales		20,218		12.3	%		17,991		10.2	%
Gross profit		144,724		87.7	%		158,448		89.8	%

Sales for the nine months ended September 30, 2019, were $164.9 million, a decrease of 6.5% from $176.4 million in the prior year period. The decrease was due to zero sales of Bilive^® and lower sales in Inlive^®. The sales decrease was partly offset by sales increases in Healive^®, the influenza vaccine, and the mumps vaccine. In addition, $8.9 million of the decline in sales for the first nine months of 2019 were attributable to the depreciation of the Chinese renminbi against the U.S. dollar.

Gross profit in the nine months ended September 30, 2019, was $144.7 million compared to gross profit of $158.4 million in the prior year period. Gross margin was 87.7% compared to 89.8% in the prior year period. The decrease of gross margin was due to a change in sales mix, with a higher proportion of sales of the influenza vaccine, which has a lower profit margin.

Selling, general and administrative expenses in the nine months ended September 30, 2019, were $88.2 million compared to $96.3 million in the prior year period. The Company incurred lower legal and consulting fees associated with the Company’s ongoing litigation matters in the 2019 period.

R&D expenses in the nine months ended September 30, 2019, were $16.5 million compared to $14.8 million in the prior year period.

Net income in the nine months ended September 30, 2019, was $32.4 million compared to $35.8 million in the prior year period. Net income decreased primarily due to lower revenue.

Net income attributable to common shareholders was $18.1 million, or $0.19 per basic and diluted share, compared to net income attributable to common shareholders of $22.9 million, or $0.37 per basic and $0.36 per diluted share, in the prior year period.

Excluding the implementation of the Rights Agreement, as described above, and the newly issued common and preferred shares, basic and diluted earnings per share for the nine months ended September 30, 2019, would be $0.31 and $0.30, respectively.

4

Non-GAAP adjusted EBITDA was $45.6 million in the nine months ended September 30, 2019, compared to $52.6 million in the prior year period. Non-GAAP net income in the nine months ended September 30, 2019, was $34.5 million compared to $38.9 million in the prior year period. Non-GAAP diluted earnings per share in the nine months ended September 30, 2019, were $0.21 per share compared to $0.41 per share in the prior year period. Non-GAAP diluted earnings per share in the nine months ended September 30, 2019, excluding the implementation of the Rights Agreement and the newly issued common and preferred shares, would be $0.32 per share. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement.

As of September 30, 2019, cash and cash equivalents totaled $156.7 million compared to $158.2 million as of December 31, 2018. In the nine months ended September 30, 2019, net cash provided by operating activities was $12.6 million, net cash used in investing activities was $10.2 million, and net cash used in financing activities was $1.0 million, including loan repayment of $3.3 million. As of September 30, 2019, the Company had $3.7 million in bank loans due within one year. The Company expects that its current cash position will be able to support its operations for at least the next 12 months.

The Company’s Interim Financial Statements are prepared and presented in accordance with U.S. GAAP. However, the Interim Financial Statements have not been audited or reviewed by the Company’s independent registered accounting firm.

Legal Proceedings

As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the “Antigua Judgment”), finding in the Company’s favor in full, dismissing 1Globe’s claim and declaring that the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s rights or shareholding or otherwise distributing the exchange shares to the Company’s shareholders who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal against the Antigua Judgment was heard in the week of September 16, 2019, and the appeal decision is now pending.

5

As disclosed previously, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware seeking a determination whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims, and a third-party complaint against the Company and Mr. Weidong Yin alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order providing that the Company not distribute any of the Exchange Shares to the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stayed the Delaware litigation pending the outcome of 1Globe’s appeal of the Antigua Judgment.

Status of Exchange Shares and Trading in the Company’s Shares

As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgment and final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time of issuance of the Exchange Shares to the trust and the Company is currently unable to estimate when trading will resume, or whether Nasdaq will take any additional action regarding the trading of the Company’s common shares.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in Asia and South America. For more information please see the Company’s website at www.sinovac.com.

6

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the United States federal securities laws. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that might cause such a difference include our inability to compete successfully in the competitive and rapidly changing marketplace in which we operate, failure to retain key employees, cancellation or delay of projects, failure to satisfy regulatory and other requirements, disapproval or delay in approval of new products by regulatory bodies, disruptions to our operations, the results of any pending litigation (including litigation relating to the 2018 annual general meeting, the validity of our Rights Agreement, and the issuance of the Exchange Shares), Nasdaq’s halt in trading of the Company’s securities and any future action taken by Nasdaq regarding the trading of the Company’s securities, and adverse general economic conditions in China, the United States and elsewhere. These risks and other factors include those listed under “Risk Factors” and elsewhere in our Annual Report on Form 20-F as filed with the Securities and Exchange Commission. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company assumes no obligation to update the forward-looking information contained in this release.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, Sinovac uses the following non-GAAP financial measures: non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS.  For more information on these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures” in this results announcement.

Sinovac believes that non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that Sinovac includes in net income and diluted EPS. Sinovac believes that non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS should not be considered in isolation or construed as an alternative to income from operations, net income, diluted EPS, or any other measure of performance or as an indicator of Sinovac’s operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies.  Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data.

7

Non-GAAP adjusted EBITDA represents net income and excludes interest and financing expenses, interest income, net other income (expenses) and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based compensation expenses, amortization and depreciation that Sinovac does not believe are reflective of the core operating performance during the periods presented.

Non-GAAP net income represents net income before share-based compensation expenses and foreign exchange gain or loss.

Non-GAAP diluted EPS represents non-GAAP net income attributable to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options.

Contact

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279-9871 or

+86-10-5693-1897

Fax: +86-10-6296-6910

Email: ir@sinovac.com

ICR Inc.

Bill Zima

U.S.: 1-646-308-1707

Email: william.zima@icrinc.com

8

SINOVAC BIOTECH LTD.

Consolidated Balance sheets

As of September 30, 2019 and December 31, 2018

(Expressed in thousands of U.S. Dollars)

	September 30, 2019			December 31, 2018
		(Unaudited)
Current assets
Cash and cash equivalents	$	156,697		$	158,170
Short-term investment		19,587			18,908
Accounts receivable - net		104,809			74,464
Income tax receivable		-			2,999
Inventories		29,465			25,091
Prepaid expenses and deposits		2,803			4,543
Total current assets		313,361			284,175
Property, plant and equipment - net		72,125			70,920
Prepaid land lease payments		7,816			8,304
Right-of-use asset		7,630			-
Long-term inventories		92			90
Long-term prepaid expenses to a related party		23			23
Prepayment for acquisition of equipment		1,416			470
Deferred tax assets		8,188			5,798
Total assets		410,651			369,780
Current liabilities
Short-term bank loans and current portion of long-term bank loans		3,742			3,321
Accounts payable and accrued liabilities		55,187			49,991
Income tax payable		5,012			-
Deferred revenue		3,518			2,907
Deferred government grants		2,227			1,986
Dividend payable		3,616			-
Lease liability		965			-
Total current liabilities		74,267			58,205
Deferred government grants		5,617			5,961
Long-term bank loans		-			3,890
Deferred revenue		87			90
Loan from a non-controlling shareholder		7,835			6,705
Lease liability		6,273			-
Other non-current liabilities		2,903			3,001
Total long-term liabilities		22,715			19,647
Total liabilities		96,982			77,852
Commitments and contingencies
Equity
Preferred stock		15			-
Common stock		99			71
Additional paid-in capital		207,211			204,998
Accumulated other comprehensive loss		(9,592	)		(2,099	)
Statutory surplus reserves		26,643			26,643
Accumulated earnings		41,938			23,820
Total shareholders' equity		266,314			253,433
Non-controlling interests		47,355			38,495
Total equity		313,669			291,928
Total liabilities and equity	$	410,651		$	369,780

9

SINOVAC BIOTECH LTD.

Consolidated Statements of Comprehensive Income

For the three and nine months ended September 30, 2019 and 2018

(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)

	Three months ended September 30						Nine months ended September 30
	2019			2018			2019			2018
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Sales	$	64,343		$	53,949		$	164,942		$	176,439
Cost of sales		10,347			4,654			20,218			17,991
Gross profit		53,996			49,295			144,724			158,448
Selling, general and administrative expenses		34,402			28,476			88,169			96,302
Provision (recovery) for doubtful accounts		16			(132	)		139			2,444
Research and development expenses		5,657			4,691			16,496			14,765
Loss on disposal of property, plant and equipment		177			51			230			69
Government grants recognized in income		(22	)		(128	)		(69	)		(175	)
Total operating expenses		40,230			32,958			104,965			113,405
Operating income		13,766			16,337			39,759			45,043
Interest and financing expenses		(147	)		(254	)		(491	)		(904	)
Interest income		664			697			1,402			1,624
Other income, net		273			(52	)		616			94
Income before income taxes		14,556			16,728			41,286			45,857
Income tax expense		(2,858	)		(3,479	)		(8,891	)		(10,039	)
Net Income		11,698			13,249			32,395			35,818
Less: Income attributable to non-controlling interests		(3,904	)		(4,387	)		(10,661	)		(12,871	)
Net income attributable to shareholders of Sinovac		7,794			8,862			21,734			22,947
Preferred stock dividends		(1,512	)		-			(3,616	)		-
Net income attributable to common shareholders of Sinovac		6,282			8,862			18,118			22,947
Net income		11,698			13,249			32,395			35,818
Other comprehensive income, net of tax of nil
Foreign currency translation adjustments		(9,059	)		(5,849	)		(9,294	)		(11,276	)
Comprehensive income		2,639			7,400			23,101			24,542
Less: comprehensive income attributable to non-controlling interests		(2,129	)		(3,197	)		(8,860	)		(10,963	)
Comprehensive income (loss) attributable to shareholders of Sinovac	$	510			4,203		$	14,241			13,579
Earnings per share
Basic net income per share		0.06			0.12			0.19			0.37
Diluted net income per share		0.06			0.12			0.19			0.36
Weighted average number of shares of common stock outstanding
Basic		98,908,243			71,121,161			93,520,043			62,571,716
Diluted		99,090,290			71,393,550			93,705,346			62,914,102

10

SINOVAC BIOTECH LTD.

Consolidated Statements of Cash Flows

For the three and nine months ended
September 30, 2019 and 2018

(Expressed in thousands of U.S. Dollars)  

	Three months ended September 30						Nine months ended September 30
	2019			2018			2019			2018
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Cash flows provided by operating activities
Net income		11,699			13,249			32,396			35,818
Adjustments to reconcile net income to net cash provided (used in) by operating activities:
- Deferred income taxes		(1,374	)		757			(2,716	)		(706	)
- Share-based compensation		751			724			2,253			3,555
- Inventory provision		151			23			334			2,499
- Provision for doubtful accounts		16			(132	)		139			2,444
- Loss on disposal and impairment of property, plant and equipment		177			51			230			69
- Depreciation of property, plant and equipment and amortization of licenses		1,214			1,282			3,433			3,771
- Amortization of prepaid land lease payments		59			60			180			189
- Government grants recognized in income		(22	)		(128	)		(69	)		(175	)
Changes in:
- Accounts receivable		(12,291	)		2,539			(34,678	)		(36,739	)
- Inventories		1,892			(3,639	)		(5,890	)		(9,059	)
- Income tax payable		4,292			(1,222	)		8,486			(6,656	)
- Prepaid expenses and deposits		1,061			459			1,260			34
- Deferred revenue		1,056			7,679			752			3,773
- Accounts payable and accrued liabilities		2,917			(8,392	)		6,758			1,590
- Other non-current liablitites		9			(158	)		(244	)		(158	)
Net cash provided by operating activities		11,607			13,152			12,624			249
Cash flows provided by (used in) financing activities
- Proceeds from bank loans		-			5,780			-			19,180
- Repayments of bank loans		(2,005	)		(6,642	)		(3,327	)		(30,433	)
- Proceeds from issuance of common stock, net of share issuance costs		-			85,292			3			85,304
- Government grants received		592			1,205			851			2,010
- Loan from a non-controlling shareholder		1,457			-			1,457			-
Net cash provided by (used in) financing activities		44			85,635			(1,016	)		76,061
Cash flows used in investing activities
- Purchase of short-term investments		(1,457	)		(18,734	)		(1,457	)		(18,734	)
- Proceeds from disposal of equipment		-			18			12			18
- Acquisition of property, plant and equipment		(2,368	)		(1,846	)		(8,713	)		(4,705	)
Net cash used in investing activities		(3,825	)		(20,562	)		(10,158	)		(23,421	)
Effect of exchange rate changes on cash and cash equivalents and restricted cash		(2,822	)		(1,807	)		(2,923	)		(4,325	)
Increase (decrease) in cash and cash equivalents and restricted cash		5,004			76,418			(1,473	)		48,564
Cash and cash equivalents and restricted cash, beginning of period		151,693			88,110			158,170			115,964
Cash and cash equivalents and restricted cash, end of period		156,697			164,528			156,697			164,528

11

SINOVAC BIOTECH LTD.

Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures

For the three and nine months ended September 30, 2019 and 2018

(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)

	Three months ended September 30						Nine months ended September 30
	2019			2018			2019			2018
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Net income		11,698			13,249			32,395			35,818
Adjustments:
Share-based compensation		751			724			2,253			3,555
Depreciation and amortization		1,273			1,342			3,613			3,960
Interest and financing expenses, net of interest income		(517	)		(443	)		(911	)		(720	)
Net other (income) expense		(273	)		52			(616	)		(94	)
Income tax expense		2,858			3,479			8,891			10,039
Non-GAAP adjusted EBITDA		15,790			18,403			45,625			52,558
Net income		11,698			13,249			32,395			35,818
Add: Foreign exchange (gain) loss		87			939			(164	)		(473	)
Add: Share-based compensation		751			724			2,253			3,555
Non-GAAP net income		12,536			14,912			34,484			38,900
Net income attributable to common shareholders of Sinovac for computing diluted earnings per share		6,282			8,862			18,118			22,947
Add: Non-GAAP adjustments to net income		550			1,663			1,443			3,082
Non-GAAP net income attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share		6,832			10,525			19,561			26,029
Weighted average number of shares on a diluted basis		99,090,290			71,393,550			93,705,346			62,914,102
Diluted earnings per share		0.06			0.12			0.19			0.36
Add: Non-GAAP adjustments to net income per share		0.01			0.02			0.02			0.05
Non-GAAP Diluted earnings per share		0.07			0.14			0.21			0.41

12